Jul 12, 2021 08:41 AM IST
If approved, Zydus Cadila's jab will be the fifth COVID-19 vaccine to get approved in India after Covishield, Covaxin, Sputnik V and Moderna.
- Jul 10, 2021 01:21 PM IST
Managing Director of Zydus Group Sharvil Patel says the company has invested Rs. 400-500 crore for the development of ZyCoV-D, the world’s first plasmid DNA vaccine for human use.
- Jul 02, 2021 02:49 PM IST
The company has received final approval from the United States Food and Drug Administration (USFDA) to market Emtricitabine and Tenofovir Disoproxil Fumarate tablets, 100 mg/150 mg, 133 mg/200 mg and 167 mg/250 mg, Zydus Cadila said in a statement.
- Jul 02, 2021 02:41 PM IST
Zydus Cadila conducted trials of ZyCoV-D at 50 sites spread across the country, making it the largest such trial in the country. It is also the first COVID vaccine in India to be tested among the 12-18 age group
- Jun 27, 2021 09:24 AM IST
The Centre said that a total of 51.6 crore COVID-19 vaccine doses would be made available by July 31 of which 35.6 crore have already been provided.
- Jun 25, 2021 12:33 PM IST
The Ahmedabad-based drug maker has received approval from the US Food and Drug Administration (USFDA) for the injection in the strengths of 100mg/vial, 500 mg/vial, and 1000 mg/vial, single-dose vials, Zydus Cadila said in a statement.
- Jun 14, 2021 12:00 PM IST
Zydus Cadila has received tentative approval from the US Food and Drug Administration (USFDA) to market Brivaracetam tablets, in the strengths of 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg, Cadila Healthcare said in a regulatory filing.
- Jun 04, 2021 08:50 AM IST
The antibody cocktail therapy is most suited for high-risk COVID-19 patients within the first 10 days of onset of symptoms and meet any of the listed criteria such as age being 65 years or above.
- May 24, 2021 11:13 AM IST
The company has launched Trastuzumab Emtansine, the first antibody drug conjugate (ADC) biosimilar and a highly effective drug for treating both early and advanced HER2 positive breast cancer, under the brand name Ujvira, Zydus Cadila said in a statement.
- May 11, 2021 02:42 PM IST
The reduction in usage of supplemental oxygen, as claimed by Zydus, could come as a relief to states that are struggling in the COVID-19 fight due to the stressed supply of medical oxygen.
- May 05, 2021 09:38 AM IST
Zydus Cadila is planning to produce 10 million doses per month of its COVID-19 vaccine, to begin with, and subsequently raise it to 20 million doses.
- Apr 23, 2021 03:17 PM IST
The company has claimed that 91.15 percent of COVID-19 patients treated with Virafin were RT-PCR negative by day 7.
- Apr 23, 2021 11:11 AM IST
Propafenone is known as an anti-arrhythmic drug. It works by blocking the activity of certain electrical signals in the heart that can cause an irregular heartbeat.
- Apr 08, 2021 01:21 PM IST
Zydus Cadila has received final approval from the US Food and Drug Administration (USFDA) to market Ibrutinib Capsules in the strengths of 70 mg and 140 mg, Cadila Healthcare said in a regulatory filing.
- Mar 24, 2021 04:47 PM IST
Remdesivir is a critical drug in the treatment of COVID-19. "This move to further revise the prices will go a long way in helping patients during these critical times," Zydus Cadila said in a statement.
- Mar 08, 2021 05:36 PM IST
Founded in 2009, Multiples PE is headed by CEO & Founder Renuka Ramnath, the former MD & CEO of ICICI Ventures. In the pharma & healthcare segment, Multiples PE has invested in firms like Natco Pharma, Encube Ethicals and Bengaluru-based Vikram Hospitals.
- Feb 25, 2021 01:22 PM IST
Zydus Cadila has received final approval from the United States Food and Drug Administration (USFDA) to market Nortriptyline Hydrochloride capsules USP, in strengths of 10 mg, 25 mg, 50 mg and 75 mg, Cadila Healthcare said in a regulatory filing.
- Jan 28, 2021 11:25 AM IST
Zydus Cadila, which is a part of Cadila Group, said orphan drug designation provides eligibility for certain development incentives, including tax credits for qualified clinical testing, prescription drug user fee exemptions and seven-year marketing exclusivity upon USFDA approval.
- Jan 20, 2021 08:44 PM IST
In the initial phase, India will inoculate about one crore healthcare workers. This will be followed by two crore frontline workers, police, armed forces, municipal workers, revenue staff and others. In the third phase, 27 crore people above 50 years of age and those with co-morbidities.
- Jan 03, 2021 05:46 PM IST
The company will now be initiating Phase III clinical trial in around 30,000 volunteers, Zydus Cadila said in a statement.
- Dec 24, 2020 10:15 PM IST
Cadila Healthcare said its vaccine was found to be well tolerated and immunogenic in the Phase I/II clinical trials.
- Dec 09, 2020 03:32 PM IST
Fast Track is a process of the USFDA to expedite the review of drugs to treat serious conditions and fill an unmet medical need. A drug that receives Fast Track Designation is eligible for accelerated approval and priority review, if the relevant criteria are met, Zydus Cadila said in a statement.
- Dec 02, 2020 05:45 PM IST
India's COVID-19 vaccination drive will be among the largest in the world and is likely to happen in phases.
- Nov 28, 2020 03:38 PM IST
PM Modi visited Zydus Cadila’s manufacturing facility near Ahmedabad, as he began his three-city visit to review ongoing coronavirus vaccine development work.
- Nov 27, 2020 03:06 PM IST
An official said that the prime minister is likely to arrive at the plant around 9.30 am.